Hemova improves clinical outcomes for kidney failure patients, helping them live longer, healthier lives, spending less time in the hospital
Therapeutics (Pharma / Biotech)
In the US, over half a million patients suffer from chronic kidney failure (CKF). Most are dependent on hemodialysis to filter their blood. Unfortunately, more than 100,000 patients/year die from CKF, a large reason being the failure of the interface between the patient and the hemodialysis machine known as a “vascular access”. At Hemova, we have developed a blood access device that is safer and more reliable than current solutions; helping to keep our patients healthier and prolong their lives.